Abstracts tagged "inflammatory bowel disease (IBD)"

Abstract Number: 136 • 2020 Pediatric Rheumatology Symposium
Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center
Sarah Kodama¹, Deepti Gupta ², Erin Sullivan ³ and Yongdong Zhao ⁴, ¹School of Medicine, Virginia Commonwealth University, Richmond, ²Pediatric Dermatology, School of Medicine, University of Washington, Seattle, ³Seattle Children's Research Institute, Seattle, ⁴University of Washington, Seattle
Background/Purpose: Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) has been increasingly reported in the adult population. Systematic studies in pediatric population are…
Abstract Number: 102 • 2020 Pediatric Rheumatology Symposium
Implications of Positive Tests for ANCA in a Pediatric Population
Karen James¹, Peter Merkel ² and Aimee Hersh ³, ¹University of Utah, 84113, Utah, ²University of Pennsylvania, Philadelphia, ³University of Utah Primary Children's Hospital, Salt Lake City
Background/Purpose: Testing for ANCA, particularly performed by ELISA (anti-MPO/PR3) is highly sensitive and specific for ANCA-associated vasculitis (AAV). However ANCA testing may be used in…
Abstract Number: 558 • 2019 ACR/ARP Annual Meeting
Frequency and Characteristics of Inflammatory Bowel Disease in Spondyloarthritis with Biological Therapy: Study of 270 Patients from the Same Center
Itziar Calvo-Zorrilla¹, María Luz García-Vivar ¹, Oihane Ibarguengoitia-Barrena ¹, David Montero-Seisdedos ¹, Lucía Vega-Alvarez ¹, Juan María Blanco-Madrigal ¹, Olaia Begoña Fernandez-Berrizbeitia ¹, María Esther Ruiz-Lucea ¹, Ignacio Torre-Salaberri ¹, Ana Rosa Intxaurbe-Pellejero ¹, Clara Eugenia Pérez-Velasquez ¹, Eduardo Cuende-Quintana ¹, Natalia Andrea Rivera-García ¹, María Jesus Allande-López-Linares ¹, Helena Ugarte-Zuazo ¹, Iñigo Gorostiza-Hormaeche ² and Eva Galíndez-Agirregoikoa ¹, ¹Rheumatology Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain, ²Investigation Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain
Background/Purpose: Inflammatory bowel disease (IBD) is an extra-articular manifestation that can appear in spondyloarthritis (SpA), as well as uveitis and psoriasis. Its prevalence is 5-10%,…
Abstract Number: 565 • 2019 ACR/ARP Annual Meeting
Evidence-Based Recommendations for the Management of Enteropathic Arthritis: A Rheumatology – Gastroenterology Collaborative Initiative
Gulen Hatemi ¹, Servet Akar ², Hale Akpinar ³, Pamir Atagunduz ⁴, Goksel Bengi ³, Gercek Can ⁵, Aykut Ferhat Celik ⁶, Sinem Nihal Esatoglu⁷, Onay Gercik ⁸, Hulya Hamzaoglu ⁹, Murat Inanc ¹⁰, Gokhan Kabacam ¹¹, Ismail Hakki Kalkan ¹², Levent Kilic ¹³, Fatos Onen ¹⁴, Ahmet Tezel ¹⁵, Murat Toruner ¹⁶ and Sedat Kiraz ¹³, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Behcet's Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ³Dokuz Eylul University, Faculty of Medicine, Department of Internal Medicine, Division of Gastroenterology, Izmir, Turkey, ⁴Marmara University Faculty of Medicine,Department of Rheumatology, Istanbul, Turkey, Istanbul, Turkey, ⁵Dokuz Eylul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Izmir, Turkey, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁷Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁸Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, Izmir, Turkey, ⁹Acibadem University, Acibadem Fulya Hospital, Department of Gastroenterology, Istanbul, Turkey, ¹⁰Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ¹¹Ankara Guven Hospital, Department of Gastroenterology, Ankara, Turkey, ¹²Türkiye Yüksek Ihtisas Training and Research Hospital, Department of Gastroenterology, Ankara, Turkey, ¹³Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ¹⁴Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁵Trakya University, Faculty of Medicine, Department of Internal Medicine, Division of Gastroenterology, Edirne, Turkey, ¹⁶Ankara University School of Medicine, Department of Gastroenterology,, Ankara, Turkey
Background/Purpose: Management of enteropathic arthritis may be challenging due to differences in treatment response of inflammatory bowel diseases and arthritis to different therapeutic modalities, which…
Abstract Number: 566 • 2019 ACR/ARP Annual Meeting
Temporal Relationship Between Enteropathic Spondylitis Symptoms/diagnosis and Inflammatory Bowel Diseases Diagnosis: HUR-BIO Real Life Results
Bayram Farisoğulları¹, Gozde Kubra Yardımcı ¹, Alper Sarı ¹, Berkan Armagan ², Emre Bilgin ¹, Ertugrul Cagri Bolek ¹, Levent Kilic ³, Omer Karadag ⁴, Ali Akdoğan ¹, Şule Apras Bilgen ³, Ali İhsan Ertenli ¹, Sedat Kiraz ³ and Umut Kalyoncu ⁵, ¹Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ²Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, ³Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁴Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey, ⁵Hacettepe University Department of Rheumatology, Ankara, Turkey
Background/Purpose: The correlation between the time frame of the symptoms/diagnosis of spondylitis and the diagnosis of inflammatory bowel disease (IBD) on patients of enteropathic spondylitis (eSpA) is not precisely…
Abstract Number: 579 • 2019 ACR/ARP Annual Meeting
Is There an Impact of Uveitis, Psoriasis and Inflammatory Bowel Disease on Musculoskeletal Disease Activity and Function in Axial Spondyloarthritis?
Imke Redeker¹, Johanna Callhoff ², Falk Hoffmann ³, Hildrun Haibel ⁴, Joachim Sieper ⁴, Angela Zink ⁵ and Denis Poddubnyy ⁶, ¹Charité – Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³Carl von Ossietzky University, Oldenburg, Germany, ⁴Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ⁵German Rheumatism Research Centre and Charité University medicine, Berlin, Germany, ⁶Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany
Background/Purpose: Uveitis, psoriasis and inflammatory bowel disease (IBD) are common in axial spondyloarthritis (axSpA) but data on their impact on activity of musculoskeletal manifestations and…
Abstract Number: 613 • 2019 ACR/ARP Annual Meeting
Can Fecal Calprotectin Predict Future Development of Inflammatory Bowel Disease in Axial Spondyloarthritis Patients? – TReasure Real-Life Preliminary Data
Gozde Kubra Yardımcı ¹, Ozan Cemal içaçan ², Gokhan Kabadayi ³, Bayram Farisoğulları ¹, Cemal Bes ⁴, Servet Akar ⁵ and Umut Kalyoncu⁶, ¹Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ²University of Health Sciences, Bakırköy Sadi Konuk Research and Training Hospital, Rheumatology, İstanbul, ³Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ⁴University of Medical Sciences, İstanbul, Turkey, ⁵Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ⁶Hacettepe University Department of Rheumatology, Ankara, Turkey
Background/Purpose: Inflammatory bowel disease (IBD) is frequently seen in patients with axial spondyloarthritis (axSpA). This study aimed to investigate whether fecal calprotectin levels could predict…
Abstract Number: 1093 • 2019 ACR/ARP Annual Meeting
The US Prevalence of Inflammatory Bowel Disease and Associated Axial Pain: Data from the National Health & Nutrition Examination Survey (NHANES)
Oleg Stens¹, Charles Dillon ², Frederick W. Miller ³ and Michael Weisman ⁴, ¹Harbor-UCLA Medical Center, Torrance, CA, ²National Institutes of Health, Bethesda, MD, ³NIEHS, NIH, Bethesda, MD, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Associations between ulcerative colitis (UC) and Crohn’s disease, known together as inflammatory bowel disease (IBD), with axial pain, inflammatory back pain (IBP) and spondyloarthritis…
Abstract Number: 1115 • 2019 ACR/ARP Annual Meeting
Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab (REMICADE)
Bruno Emond ¹, Kay Sadik ², Marie-Hélène Lafeuille ¹, Willy Wynant ¹, Aurélie Côté-Sergent ¹, Patrick Lefebvre ¹, Kimberly Woodruff ² and Timothy Fitzgerald³, ¹Analysis Group, Inc, Montreal, QC, Canada, ²Janssen Scientific Affairs, LLC, Titusville, NJ, ³Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Chronic inflammatory diseases (CIDs) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis (PsO), ankylosing spondylitis (AS), Crohn's disease (CD), and ulcerative colitis…
Abstract Number: 1478 • 2019 ACR/ARP Annual Meeting
Systematic Literature Review and Network Meta-Analysis Comparing Incidence of Uveitis and IBD in Axial Spondyloarthritis Patients Treated with Anti-TNF versus Anti-IL17A in Placebo Controlled Randomized Trials
Damien Roche¹, Martin Badard ¹, Laurent Boyer ², Pierre Lafforgue ¹ and Thao Pham ¹, ¹Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ²Aix-Marseille University, EA 3279 Research Unit, 13,000 Marseille, France, Marseille, France
Background/Purpose: Inflammatory bowel diseases (IBD) and anterior uveitis (AU) are frequent extra-articular features of axial spondyloarthritis (axSpA). Although effect of anti-TNF on IBD and AU…
Abstract Number: 1522 • 2019 ACR/ARP Annual Meeting
Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks
Sergio Schwartzman¹, Atul Deodhar ², Andris Kronbergs ³, Silvia Santisteban ³, Sandra Garces ³, David Sandoval ³, Jeffrey Lisse ³, Fangyi Zhao ³, Denis Poddubnyy ⁴ and James Rosenbaum ⁵, ¹The Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, ²Oregon Health & Science University, Portland, OR, ³Eli Lilly and Company, Indianapolis, IN, ⁴Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁵Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, Portland, OR
Background/Purpose: Radiographic axial spondyloarthritis (r-axSpA) is a chronic inflammatory disease involving the axial skeleton; inflammatory bowel disease (IBD) and acute anterior uveitis (AAU) are common…
Abstract Number: 699 • 2018 ACR/ARHP Annual Meeting
New Onset/Recurrence of Inflammatory Arthralgia/Spondyloarthritis in Patients Treated with Vedolizumab for Intestinal Bowel Disease
Silvia Tamanini¹, Micaela Fredi², Chiara Bazzani¹, Maria Grazia Lazzaroni³, Melissa Fernandes⁴, Cecilia Nalli³, Angela Tincani³ and Franco Franceschini², ¹Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ²Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁴Autoimmune Unit/Internal Medicine Department, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central (C.H.L.C), Lisbona, Portugal
Background/Purpose: Vedolizumab (VDZ) is a monoclonal antibody approved for inflammatory bowel disease, with a gut-specific mechanism of action, binding to α4β7 integrine expressed on gut-homing…
Abstract Number: 1828 • 2018 ACR/ARHP Annual Meeting
Gut-Joint T Cell Trafficking in a Model of Bacteria-Driven Murine IBD-Spa
Eric Norman¹, Adam Lefferts¹ and Kristine A Kuhn^1,2, ¹Rheumatology, University of Colorado Denver, Aurora, CO, ²Mucosal Inflammation Program, University of Colorado Denver, Aurora, CO
Background/Purpose: Significant bacterial dysbiosis occurs in individuals with IBD and SpA, and individuals with SpA have evidence of circulating intestinal-derived cells, lending credence to the…
Abstract Number: 1831 • 2018 ACR/ARHP Annual Meeting
Intestinal Inflammatory Regulation in Murine and Human Spondyloarthropathy Requires High-Affinity T Cell Receptor-Zeta Chain-Associated Protein (ZAP)70-Mediated Runt-Related Transcription Factor (Runx)3 Activity
Zaied Ahmed Bhuyan¹, M. Arifur Rahman², Muralidhara Maradana¹, Ahmed Mehdi³, Giuliana Guggino⁴, Paul Leo⁵, Linda Rehaume¹, Matthew Brown⁵, Francesco Ciccia⁴ and Ranjeny Thomas¹, ¹The University of Queensland Diamantina Institute, Brisbane, Australia, ²Translational Research Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, ³Diamantina Institute, The University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Rheumatology Unit, University of Palermo, Palermo, Italy, ⁵Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia
Background/Purpose: Loss of function RUNX3 variants are associated with ankylosing spondylitis (AS) risk but the mechanism is unknown. Disturbances in immune regulation, intestinal microbial dysbiosis…
Abstract Number: 1866 • 2018 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis
Mark C. Genovese¹, Jean-Frederic Colombel², Amanda M. Gellett³, Wen Xu³ and Dana Hardin³, ¹Department of Medicine, Stanford University, Palo Alto, CA, ²Department of Gastroenterology, The Mount Sinai Hospital, New York, NY, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Increased incidence of IBD, such as Crohn’s disease (CD) and ulcerative colitis (UC), has been observed in patients (pts) with PsA or plaque psoriasis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].